MedPath

Which medicine is better for fits after head injury and when should one start it.

Phase 3
Not yet recruiting
Conditions
Health Condition 1: G405- Epileptic seizures related to external causes
Registration Number
CTRI/2024/05/067626
Lead Sponsor
ational Institute of Mental Health and Neurosciences (NIMHANS)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

MAST DURATION

Inclusion Criteria:

Patients aged =10 years with TBI managed in an NSU who have started on an phenytoin or levetiracetam due to an acute symptomatic seizure during acute hospitalisation

Patient or Legal Representative is willing and able to provide informed consent or in the absence of a legal representative, an Independent Healthcare Professional provides authorisation for patient enrolment

MAST PROPHYLAXIS

Inclusion Criteria:

Patients aged =10 years, with TBI managed in an NSU without an acute symptomatic seizure

Patient or Legal Representative is willing and able to provide informed consent or in the absence of a legal representative, an Independent Healthcare Professional provides authorisation for patient enrolment within 48 hours of admittance.

Exclusion Criteria

MAST DURATION

Unsurvivable injury

Previous history of epilepsy

Patients who are on an AED pre-TBI

Patient who has been clinically prescribed an AED other than phenytoin or levetiracetam

Unwillingness to take products containing gelatin (animal products)

Severe lactose intolerance or any known hypersensitivity to study drug or any of its excipients

MAST PROPHYLAXIS

Post-traumatic seizures

Unsurvivable injury

Previous history of epilepsy

Patients who are on an AED pre-TBI

Pregnancy or breastfeeding

Unwillingness to take products containing gelatin (animal products)

Severe lactose intolerance or any known hypersensitivity to study drug or any of its excipients

Time interval from the time of admission to NSU to randomisation exceeds 48 hours

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
MAST-DURATION: the occurrence of late post-traumatic seizure. <br/ ><br>MAST-PROPHYLAXIS: is the occurrence of an acute symptomatic seizure.Timepoint: MAST-DURATION: Within 24 months post traumatic brain injury <br/ ><br>MAST-PROPHYLAXIS: Occurrence of post-traumatic seizures within 2 weeks post TBI <br/ ><br> <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
•Extended Glasgow Outcome Scale, Neurobehavioural Symptom Inventory, quality of life (EQ-5D-5L), and Liverpool Adverse EventsTimepoint: At 6, 12, 18 and 24 months;Frequency of adverse events of special interest (unfavourable and unintended sign, symptom, or disease temporally associated with the use of trial drug, whether or not considered related to the trial drug.Timepoint: Up to 24 months;MortalityTimepoint: Death from any cause;THe frequency of post traumatic seizuresTimepoint: Within 24 months post traumatic brain injury
© Copyright 2025. All Rights Reserved by MedPath